Loregian A, Mercorelli B, Nannetti G et al (2014) Antiviral strategies against influenza virus:

towards new therapeutic approaches. Cell. Mol. Life Sci. 71:3659–3683

Mercorelli B, Luganini A, Celegato M et al (2018) Repurposing the clinically approved calcium

antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus

targeting the immediate-early 2 (IE2) protein. Antivir. Res. 150:130–136. https://doi.org/10.

1016/j.antiviral.2017.12.014

Mercorelli B, Luganini A, Nannetti G et al (2016) Drug repurposing approach identifies inhibitors

of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication.

Cell. Chem. Biol. 23:340–351. https://doi.org/10.1016/j.chembiol.2015.12.012

Mrhar A, Kopitar Z, Kozjek F et al (1979) Clinical pharmacokinetics of nitroxoline. Int. J. Clin.

Pharmacol. Ther. Toxicol. 17:476–481

Mukhopadhyay R, Roy S, Venkatadri R et al (2016) Efficacy and mechanism of action of low dose

emetine against human cytomegalovirus. PLoS Pathog. 12. https://doi.org/10.1371/journal.ppat.

1005717

Nadal M, Mas PJ, Blanco AG et al (2010) Structure and inhibition of herpesvirus DNA packaging

terminase nuclease domain. Proc. Natl. Acad. Sci. U. S. A. 107:16078–16083. https://doi.org/

10.1073/pnas.1007144107

Nosengo N (2016) Can you teach old drugs new tricks? Nature 534:314–316. https://doi.org/10.

1038/534314a

Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A (2020) A pharmacological perspective of

chloroquine in SARS-CoV-2 infection: an old drug for the fight against a new coronavirus?

Int. J. Antimicrob. Agents 56:106078. https://doi.org/10.1016/j.ijantimicag.2020.106078

Pelletier C, Prognon P, Bourlioux P (1995) Roles of divalent cations and pH in mechanism of action

of nitroxoline against Escherichia coli strains. Antimicrob. Agents Chemother. 39:707–713.

https://doi.org/10.1128/AAC.39.3.707

Ponroy N, Taveira A, Mueller NJ, Millard AL (2015) Statins demonstrate a broad anti-

cytomegalovirus activity in vitro in ganciclovir-susceptible and resistant strains. J. Med.

Virol. 87:141–153. https://doi.org/10.1002/jmv.23998

Pushpakom S, Iorio F, Eyers PA et al (2018) Drug repurposing: progress, challenges and

recommendations. Nat. Rev. Drug Discov. 18:41–58

Rastegar-Mojarad M, Ye Z, Kolesar JM et al (2015) Opportunities for drug repositioning from

phenome-wide association studies. Nat. Biotechnol. 33:342–345

Rossi B, Ponzio G, Lazdunski M (1982) Identification of the segment of the catalytic subunit of (Na

+,K+)ATPase containing the digitalis binding site. EMBO J. 1:859–861. https://doi.org/10.

1002/j.1460-2075.1982.tb01260.x

Sheahan TP, Sims AC, Graham RL et al (2017) Broad-spectrum antiviral GS-5734 inhibits both

epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9. https://doi.org/10.1126/scitranslmed.

aal3653

Singhal A, Jie L, Kumar P et al (2014) Metformin as adjunct antituberculosis therapy. Sci. Transl.

Med. 6:263ra159. https://doi.org/10.1126/scitranslmed.3009885

Sissoko D, Laouenan C, Folkesson E et al (2016) Experimental treatment with Favipiravir for Ebola

virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in

Guinea. PLoS Med. 13:e1001967. https://doi.org/10.1371/journal.pmed.1001967

Soo V, Kwan B, Quezada H et al (2016) Repurposing of anticancer drugs for the treatment of

bacterial infections. Curr. Top. Med. Chem. 17:1157–1176. https://doi.org/10.2174/

1568026616666160930131737

Sweiti H, Ekwunife O, Jaschinski T, Lhachimi SK (2017) Repurposed therapeutic agents targeting

the Ebola virus: a systematic review. Curr. Ther. Res. Clin. Exp. 84:10–21. https://doi.org/10.

1016/j.curtheres.2017.01.007

Talevi A, Bellera CL (2020) Challenges and opportunities with drug repurposing: finding strategies

to find alternative uses of therapeutics. Expert Opin. Drug Discov 15:397–401. https://doi.org/

10.1080/17460441.2020.1704729

34

A. Sharma and J. Kaur